Evofem Biosciences Inc (NASDAQ:EVFM) price target set to $9.00 by Oppenheimer

ME Staff
-
0

Analyst Ratings For Evofem Biosciences Inc (NASDAQ:EVFM)

Today, Oppenheimer set its price target on Evofem Biosciences Inc (NASDAQ:EVFM) to $9.00 per share.

There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Evofem Biosciences Inc (NASDAQ:EVFM) is Buy with a consensus target price of $10.40 per share, a potential 193.83% upside.

Some recent analyst ratings include

  • 11/23/2018-Evofem Biosciences Inc (NASDAQ:EVFM) had its Overweight rating reiterated by Cantor Fitzgerald
  • 6/27/2018-Evofem Biosciences Inc (NASDAQ:EVFM) has coverage initiated with a Outperform rating and $8.00 price target
  • 6/20/2018-Evofem Biosciences Inc (NASDAQ:EVFM) has coverage initiated with a Buy rating and $15.00 price target
  • On 11/21/2018 Russell Barrans, Insider, bought 279 with an average share price of $3.55 per share and the total transaction amounting to $990.45.
  • On 8/21/2018 Alexander A Fitzpatrick, General Counsel, bought 5,000 with an average share price of $2.21 per share and the total transaction amounting to $11,050.00.
  • On 8/16/2018 Kelly Culwell, Insider, bought 3,000 with an average share price of $2.24 per share and the total transaction amounting to $6,720.00.
  • On 8/15/2018 Thomas G Lynch, Director, bought 100,000 with an average share price of $2.26 per share and the total transaction amounting to $226,000.00.
  • On 8/10/2018 Russell Barrans, Insider, bought 3,715 with an average share price of $1.98 per share and the total transaction amounting to $7,355.70.
  • On 8/10/2018 Saundra L Pelletier, CEO, bought 10,000 with an average share price of $2.11 per share and the total transaction amounting to $21,100.00.
  • On 5/22/2018 Ltd. Invesco, Major Shareholder, bought 2,127,659 with an average share price of $4.69 per share and the total transaction amounting to $9,978,720.71.

About Evofem Biosciences Inc (NASDAQ:EVFM)
Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women. The company is also developing vaginal gel product candidate for the treatment of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Recent Trading Activity for Evofem Biosciences Inc (NASDAQ:EVFM)
Shares of Evofem Biosciences Inc closed the previous trading session at 3,50 −0,35 9,09 % with shares trading hands.